TrialCancer science2017

Phase 1/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome.

Yasunori Ueda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.